-transparent.png){kind=logo}
A patient with common variable immunodeficiency and autoimmune hemolytic anemia was given high-dose (450 mg/kg) intravenous gamma globulin (Sandoglobulin) for five days, followed by single doses of 100 to 200 mg/kg at four-week intervals or whenever the hemoglobin level and hematocrit fell or the reticulocyte count increased. This treatment was accompanied by a stabilization of hematopoietic parameters and reversal of Coombs' positivity, which have been sustained for 34 months. The use of high-dose gamma globulin for autoimmune hemolytic anemia can eliminate the need for other therapeutic modalities that may be detrimental to an immunocompromised host.
Related Publications
F E Leickly, and
R H Buckley
August 1986,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
F E Leickly, and
R H Buckley
October 1996,
Sangre,
F E Leickly, and
R H Buckley
January 1987,
Haematologica,
F E Leickly, and
R H Buckley
July 1996,
The Journal of allergy and clinical immunology,
F E Leickly, and
R H Buckley
November 1983,
Presse medicale (Paris, France : 1983),
F E Leickly, and
R H Buckley
January 1986,
Vox sanguinis,
F E Leickly, and
R H Buckley
July 1982,
The New England journal of medicine,
F E Leickly, and
R H Buckley
October 1987,
The American journal of medicine,
F E Leickly, and
R H Buckley
January 1992,
The Clinical investigator,
F E Leickly, and
R H Buckley
March 1987,
The American journal of medicine,
